Jazz Pharmaceuticals PLC

JAZZ remains in a Stage 2 advancing regime with a recent Momentum Breakout confirming continuation, but price is extremely overbought and extended above the rising 9/21 EMAs. Execution favors waiting for a pullback into the EMA support zone for trend continuation, supported by healthy volume dynamics and rising long-term trend.

• ↑Q1 2026 revenue rose 19% YoY to $1.1B, driven by sleep and oncology
• ↑Cash reserves of $2.9B fund R&D and commercial investments
• ↓Sleep drug generics set to lower ZyWave and Xyrem sales